Banner Image

Test Directory

Lung Cancer (NSCLC), ROS1 (6q22) Rearrangement, FISH

Order Code: LCROS1

Test Summary

ROS1 rearrangement has been identified in 1.7% of non small-cell lung cancer (NSCLC) by using a FISH assay. Treatment with ALK/MET tyrosine kinase inhibitors such as crizotinib (Xalkori(R)) has shown early evidence of therapeutic efficacy in ROS1-rearranged NSCLC (Bergethon, et al. J Clin Oncol. 2012;30:863-870)

Aliases

  • N/A

Specimen Collection

Order Code

LCROS1

EPIC (Premier) Code

LAB5412

Includes

N/A

CPT Code

  • 88271 (x2)
  • 88274

Billing Code

  • 671066
  • 671067

CPT Statement

Methodology

Fluorescence In Situ Hybridization (FISH)

FDA Status

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Physician Attestation of Informed Consent

N/A

Testing Laboratory

Quest Diagnostics Nichols Institute
14225 Newbrook Drive
Chantilly VA, 20153

Department

Reference Testing

Reference Range

See Laboratory Report

Setup Schedule / Expected Turnaround Time

Daily; Report available: 7 days

Specimen Collection

Billing

CPT Code

  • 88271 (x2)
  • 88274

Billing Code

  • 671066
  • 671067

CPT Statement

Result Information

Methodology

Fluorescence In Situ Hybridization (FISH)

Testing Laboratory

N/A

Reference Range

See Laboratory Report

Setup Schedule / Expected Turnaround Time

Daily; Report available: 7 days